Area of research
Infectious Diseases · Virology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, HIV Research and Treatment, COVID-19 Clinical Research Studies, and vaccines and immunoinformatics approaches.
Clonal expansion and diversification of germinal center and memory B cell responses to booster immunization in primates
SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity
Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques
Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape
Antigen presentation dynamics shape the antibody response to variants like SARS-CoV-2 Omicron after multiple vaccinations with the original strain
Memory B cell development elicited by mRNA booster vaccinations in the elderly
Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies
SARS-CoV-2 vaccination, booster, and infection in pregnant population enhances passive immunity in neonates
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination
Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins
Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans
Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis
Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens
Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans
Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population
Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants
Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting
Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection
Evolution of antibody immunity to SARS-CoV-2
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants
High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
Replication and single-cycle delivery of SARS-CoV-2 replicons